The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

Laura J. Klesse, Justin T. Jordan, Heather B. Radtke, Tena Rosser, Elizabeth Schorry, Nicole Ullrich, David Viskochil, Pamela Knight, Scott R. Plotkin, Kaleb Yohay

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint Dive into the research topics of 'The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities'. Together they form a unique fingerprint.

Medicine & Life Sciences